| 188.11 -0.92 (-0.49%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 228.14 | 1-year : | 266.47 |
| Resists | First : | 195.33 | Second : | 228.14 |
| Pivot price | 189.57 |
|||
| Supports | First : | 184.68 | Second : | 178.11 |
| MAs | MA(5) : | 188.5  |
MA(20) : | 188.54 |
| MA(100) : | 183.51 |
MA(250) : | 204.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 63.7 |
D(3) : | 62.5 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 251.99 | Low : | 163.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BDX ] has closed above bottom band by 36.1%. Bollinger Bands are 19.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 190.24 - 191.52 | 191.52 - 192.58 |
| Low: | 184.91 - 186.17 | 186.17 - 187.21 |
| Close: | 186.27 - 188.31 | 188.31 - 190 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Wed, 22 Oct 2025
What Makes Becton Dickinson & Co. (BDX) a Good Investment? - Insider Monkey
Wed, 22 Oct 2025
What Makes Becton Dickinson & Co. (BDX) a Good Investment? - Yahoo Finance
Tue, 21 Oct 2025
BDX Launches AI-Enabled Platform to Unify Healthcare Connectivity - TradingView
Mon, 20 Oct 2025
Becton, Dickinson and Company: A Dividend Idea With Diverse Medtech Portfolio To Meet Future Demand - Seeking Alpha
Mon, 20 Oct 2025
The Bull Case for Becton Dickinson (BDX) Could Change Following CFO Transition and Revenue Miss – Learn Why - simplywall.st
Mon, 20 Oct 2025
BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 287 (M) |
| Shares Float | 286 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 92.3 (%) |
| Shares Short | 3,830 (K) |
| Shares Short P.Month | 4,560 (K) |
| EPS | 5.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 88.87 |
| Profit Margin | 7.4 % |
| Operating Margin | 17.8 % |
| Return on Assets (ttm) | 3.9 % |
| Return on Equity (ttm) | 6.1 % |
| Qtrly Rev. Growth | 10.3 % |
| Gross Profit (p.s.) | 35.2 |
| Sales Per Share | 74.62 |
| EBITDA (p.s.) | 20.65 |
| Qtrly Earnings Growth | 19 % |
| Operating Cash Flow | 3,250 (M) |
| Levered Free Cash Flow | 3,370 (M) |
| PE Ratio | 34.38 |
| PEG Ratio | 0 |
| Price to Book value | 2.11 |
| Price to Sales | 2.52 |
| Price to Cash Flow | 16.59 |
| Dividend | 1.03 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|